文献速递腹部CTMR

IPMN囊灶缩小反示合并胰腺癌风险升高

Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk.
PubMed 文献 · Eur Radiol · 2026-07-10

回顾性队列纳入1103例经病理或细胞学确诊的分支胰管型或混合型IPMN患者,随访≥1年,按京都指南2024年阈值分为缩小、稳定、增长三组。结果显示囊灶缩小组的合并胰腺导管腺癌发生率最高(2.1%),多因素竞争风险模型中缩小是合并PDAC的独立危险因素(sHR 4.46)。

要点

  • IPMN囊灶缩小不应视为良性转归而降低随访强度。
  • 囊灶增长组的合并PDAC为0%源于IPMN来源癌的竞争风险。
  • 缩小组患者合并PDAC风险独立于监测囊灶本身发展。

核心结论

  • 囊灶缩小与合并胰腺导管腺癌发生风险升高独立相关(sHR 4.46;95% CI 1.62-12.30;p=0.004)。
  • 缩小反映良性病程的传统假设需重新审视,该发现仅为探索性假设生成。

研究设计与样本

  • 单中心回顾性队列研究,纳入1103例经病理或细胞学确诊的分支胰管型或混合型IPMN患者。
  • 随访时间≥1年,按京都指南2024年阈值将年囊灶变化率分为缩小(<0 mm/年)、稳定(0至<2.5 mm/年)、增长(≥2.5 mm/年)。
  • 主要结局为合并胰腺导管腺癌,IPMN来源癌作为竞争事件纳入分析。
  • 多因素Fine-Gray竞争风险回归为主要分析方法,原因别Cox回归作为敏感性分析。

关键影像表现/征象

  • 1103例中282例(25.6%)囊灶缩小,728例(66.0%)稳定,93例(8.4%)增长。
  • 合并PDAC发生频率在缩小组最高(6/282,2.1%),其次为稳定组(8/728,1.1%),增长组无合并PDAC事件(0/93)。
  • IPMN来源癌在增长组发生率最高(9/93,9.7%)。

诊断标准与关键数值

  • 调整年龄、性别、初始囊灶大小和主胰管直径后,囊灶缩小的合并PDAC亚分布风险比为4.46(95% CI 1.62-12.30;p=0.004)。
  • 原因别Cox回归一致性估计:囊灶缩小的合并PDAC风险比为4.54(95% CI 1.52-13.50;p=0.007)。
  • 年囊灶变化率分组阈值依据2024年京都指南:缩小<0 mm/年,稳定0至<2.5 mm/年,增长≥2.5 mm/年。

临床应用与阅片要点

  • 放射科医生对缩小IPMN囊灶不应减弱监测强度,此类患者合并PDAC风险升高。
  • 阅片时囊灶缩小应提示仔细排查胰腺其他部位可能存在的独立胰腺癌。
  • 增长组合并PDAC事件为0需结合IPMN来源癌高发的竞争风险背景谨慎解读。

局限性

  • 单中心回顾性设计,合并PDAC事件总数较少(n=14),结论仅为探索性。
  • 结果需要在多中心前瞻性队列中进行外部验证后方可改变临床监测实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate whether cyst shrinkage in intraductal papillary mucinous neoplasm (IPMN) is paradoxically associated with a higher risk of concomitant pancreatic ductal adenocarcinoma (PDAC).

MATERIALS AND METHODS: This retrospective cohort included 1103 patients with pathologically or cytologically confirmed branch-duct or mixed-type IPMN followed for ≥ 1 year. Patients were classified by annual cyst size change rate per the 2024 Kyoto guideline thresholds: shrinkage (< 0 mm/year), stable (0 to < 2.5 mm/year), and growth (≥ 2.5 mm/year). The primary outcome was concomitant PDAC, with IPMN-derived carcinoma as a competing event. Multivariable Fine-Gray regression compared shrinkage with a pre-specified merged non-shrinkage reference; cause-specific Cox regression served as sensitivity analysis.

RESULTS: Of 1103 patients (541 men, 562 women; mean age, 67.3 ± 9.8 years), 282 (25.6%) showed shrinkage, 728 (66.0%) remained stable, and 93 (8.4%) showed growth. Concomitant PDAC was most frequent in shrinkage (6/282, 2.1%), followed by stable (8/728, 1.1%), with no events in growth (0/93). IPMN-derived carcinoma was most frequent in growth (9/93, 9.7%). Adjusted for age, sex, initial cyst size, and main pancreatic duct diameter, shrinkage was independently associated with concomitant PDAC (subdistribution hazard ratio 4.46; 95% CI 1.62-12.30; p = 0.004); cause-specific Cox regression yielded a concordant estimate (hazard ratio 4.54; 95% CI 1.52-13.50; p = 0.007).

CONCLUSION: In this single-center retrospective cohort, cyst shrinkage was associated with an increased incidence of concomitant PDAC, contrary to the prevailing assumption that shrinkage reflects a benign course. Given the modest number of concomitant PDAC events (n = 14), these findings are hypothesis-generating and exploratory; external validation in multicenter prospective cohorts is required before clinical surveillance practice is modified.

KEY POINTS: Question Cyst shrinkage during intraductal papillary mucinous neoplasm surveillance is considered reassuring, but its association with concomitant pancreatic cancer risk remains unclear. Findings Shrinkage was paradoxically associated with higher concomitant pancreatic cancer risk (subdistribution hazard ratio 4.46); the growth group's 0% rate reflected competing risks from IPMN-derived carcinoma. Clinical relevance Radiologists should not reduce surveillance intensity for shrinking intraductal papillary mucinous neoplasm cysts, as these patients carry an elevated risk of concomitant pancreatic cancer developing independently of the monitored cyst.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fukui, Yoshioka, Sato, et al. Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk. Eur Radiol. 2026. PMID: 42432261. doi:10.1007/s00330-026-12740-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。